Sex Differences in Management and Outcomes of Cardioembolic Stroke: Post HOC Analyses of the RELAXED Study

J Stroke Cerebrovasc Dis. 2021 Apr;30(4):105613. doi: 10.1016/j.jstrokecerebrovasdis.2021.105613. Epub 2021 Jan 30.

Abstract

Introduction: Experimental models have clearly demonstrated sex differences in the pathophysiology of stroke and prognosis, however clinical evidence remains elusive. In this study, we examined sex differences as a post hoc analysis of RELAXED (Recurrent Embolism Lessened by rivaroxaban, an anti-X agent, of Early Dosing for acute IS and TIA with atrial fibrillation) Study.

Methods: We stratified study participants by sex and compared baseline and clinical characteristics as well as clinical outcomes. The primary outcome measure was a good outcome defined as a modified Rankin Scale score of 0-2 at 90 days after stroke. Secondary outcomes were mortality at 90 days, intracranial hemorrhage within 90 days, and recurrence of stroke or transient ischemic attack within 90 days. We constructed a logistic regression model to estimate the adjusted odds ratio of female patients compared with male patients for the primary and secondary outcomes.

Results: Of 1303 patients, most were male (57.7%) with a mean age of 74.5 years. Female patients were older with a mean age of 80.6 ± 8.9 years and had significantly less frequent anticoagulation therapy before onset of stroke and more severe NIHSS scores. Good outcome was observed in 51.2% and 63.3% of the females and males (p < 0.0001). The adjusted odds ratio of a good outcome in females was 1.12 (95% confidence interval, 0.44-2.87) (p = 0.81). There were no sex differences in secondary outcomes.

Conclusion: Adjusted regression analysis found no sex difference in the treatment outcomes at 90 days after stroke with non-valvular atrial fibrillation.

Keywords: Logistic regression analysis; RELAXED Study; Sex difference; Stroke.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / mortality
  • Disability Evaluation
  • Embolic Stroke / diagnosis
  • Embolic Stroke / etiology
  • Embolic Stroke / mortality
  • Embolic Stroke / prevention & control*
  • Factor Xa Inhibitors / administration & dosage*
  • Female
  • Health Status Disparities*
  • Healthcare Disparities*
  • Humans
  • Intracranial Hemorrhages / chemically induced
  • Ischemic Attack, Transient / diagnosis
  • Ischemic Attack, Transient / etiology
  • Ischemic Attack, Transient / mortality
  • Ischemic Attack, Transient / prevention & control*
  • Japan
  • Male
  • Middle Aged
  • Recurrence
  • Registries
  • Risk Assessment
  • Risk Factors
  • Rivaroxaban / administration & dosage*
  • Sex Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban